Potential Severe Asthma Hidden in UK Primary Care.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
04 2021
Historique:
received: 08 07 2020
revised: 24 11 2020
accepted: 25 11 2020
pubmed: 15 12 2020
medline: 25 5 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Severe asthma may be underrecognized in primary care. Identify and quantify patients with potential severe asthma (PSA) in UK primary care, the proportion not referred, and compare primary care patients with PSA with patients with confirmed severe asthma from UK tertiary care. This was a historical cohort study including patients from the Optimum Patient Care Research Database (aged ≥16 years, active asthma diagnosis pre-2014) and UK patients in the International Severe Asthma Registry (UK-ISAR aged ≥18 years, confirmed severe asthma in tertiary care). In the OPCRD, PSA was defined as Global INitiative for Asthma 2018 step 4 treatment and 2 or more exacerbations/y or at Global INitiative for Asthma step 5. The proportion of these patients and their referral status in the last year were quantified. Demographic and clinical characteristics of groups were compared. Of 207,557 Optimum Patient Care Research Database patients with asthma, 16,409 (8%) had PSA. Of these, 72% had no referral/specialist review in the past year. Referred patients with PSA tended to have greater prevalence of inhaled corticosteroid/long-acting β Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.

Sections du résumé

BACKGROUND
Severe asthma may be underrecognized in primary care.
OBJECTIVE
Identify and quantify patients with potential severe asthma (PSA) in UK primary care, the proportion not referred, and compare primary care patients with PSA with patients with confirmed severe asthma from UK tertiary care.
METHODS
This was a historical cohort study including patients from the Optimum Patient Care Research Database (aged ≥16 years, active asthma diagnosis pre-2014) and UK patients in the International Severe Asthma Registry (UK-ISAR aged ≥18 years, confirmed severe asthma in tertiary care). In the OPCRD, PSA was defined as Global INitiative for Asthma 2018 step 4 treatment and 2 or more exacerbations/y or at Global INitiative for Asthma step 5. The proportion of these patients and their referral status in the last year were quantified. Demographic and clinical characteristics of groups were compared.
RESULTS
Of 207,557 Optimum Patient Care Research Database patients with asthma, 16,409 (8%) had PSA. Of these, 72% had no referral/specialist review in the past year. Referred patients with PSA tended to have greater prevalence of inhaled corticosteroid/long-acting β
CONCLUSIONS
Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.

Identifiants

pubmed: 33309935
pii: S2213-2198(20)31327-1
doi: 10.1016/j.jaip.2020.11.053
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Anti-Asthmatic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1612-1623.e9

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Dermot Ryan (D)

Usher Institute, University of Edinburgh, United Kingdom.

Heath Heatley (H)

Observational and Pragmatic Research Institute, Singapore, Singapore.

Liam G Heaney (LG)

UK Severe Asthma Network and National Registry, Queen's University Belfast, Belfast, Northern Ireland.

David J Jackson (DJ)

UK Severe Asthma Network and National Registry, Guy's and St Thomas' NHS Trust and Division of Asthma, Allergy & Lung Biology, King's College London, London, United Kingdom.

Paul E Pfeffer (PE)

UK Severe Asthma Network, Barts Health NHS Trust and Queen Mary University of London, London, United Kingdom.

John Busby (J)

UK Severe Asthma Network and National Registry, Queen's University Belfast, Belfast, Northern Ireland.

Andrew N Menzies-Gow (AN)

UK Severe Asthma Network and National Registry, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Rupert Jones (R)

Faculty of Health, University of Plymouth, Plymouth, United Kingdom.

Trung N Tran (TN)

AstraZeneca, Gaithersburg, MD.

Mona Al-Ahmad (M)

Al-Rashed Allergy Center, Ministry of Health, Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait.

Vibeke Backer (V)

Department of ENT & Centre for Physical Activity Research, Rigshospitalet and Copenhagen University, Copenhagen, Denmark.

Manon Belhassen (M)

PELyon, HESPER 7425, Claude Bernard University, Lyon, France.

Sinthia Bosnic-Anticevich (S)

Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia.

Arnaud Bourdin (A)

Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France.

Lakmini Bulathsinhala (L)

Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.

Victoria Carter (V)

Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.

Isha Chaudhry (I)

Observational and Pragmatic Research Institute, Singapore, Singapore.

Neva Eleangovan (N)

Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.

J Mark FitzGerald (JM)

Centre for Lung Health, Vancouver, Canada.

Peter G Gibson (PG)

Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia; Hunter Medical Research Institute, Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, NSW, Australia.

Naeimeh Hosseini (N)

Optimum Patient Care, Cambridge, United Kingdom.

Alan Kaplan (A)

Family Physician Airways Group of Canada, Stouffville, ON, Canada; University of Toronto, Toronto, ON, Canada.

Ruth B Murray (RB)

Optimum Patient Care, Cambridge, United Kingdom.

Chin Kook Rhee (CK)

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Eric Van Ganse (E)

PELyon, HESPER 7425, Claude Bernard University, Lyon, France.

David B Price (DB)

Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom. Electronic address: dprice@opri.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH